Results

Total Results: 4,884 records

Showing results for "end stage renal".

  1. preventiveservices.ahrq.gov/sites/default/files/wysiwyg/research/findings/ta/prp/prp-wound-care.pdf
    September 17, 2020 - and general health (e.g., status of HbA1c, diabetes, peripheral vascular disease, obesity, smoking, renal … Gender Comorbidities (e.g., status of HbA1c, diabetes, peripheral vascular disease, obesity, smoking, renal … A list of the studies excluded at the full-text review stage is in Appendix C. Key Question 1. … Several studies mentioned that if wound closure was complete prior to the end of the planned treatment … One study plans to apply dressing with PRP every 3 days until 90% wound healing, with no specific end
  2. ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/research/findings/ta/prp/prp-wound-care.pdf
    September 17, 2020 - and general health (e.g., status of HbA1c, diabetes, peripheral vascular disease, obesity, smoking, renal … Gender Comorbidities (e.g., status of HbA1c, diabetes, peripheral vascular disease, obesity, smoking, renal … A list of the studies excluded at the full-text review stage is in Appendix C. Key Question 1. … Several studies mentioned that if wound closure was complete prior to the end of the planned treatment … One study plans to apply dressing with PRP every 3 days until 90% wound healing, with no specific end
  3. www.ahrq.gov/sites/default/files/wysiwyg/research/findings/ta/prp/prp-wound-care.pdf
    September 17, 2020 - and general health (e.g., status of HbA1c, diabetes, peripheral vascular disease, obesity, smoking, renal … Gender Comorbidities (e.g., status of HbA1c, diabetes, peripheral vascular disease, obesity, smoking, renal … A list of the studies excluded at the full-text review stage is in Appendix C. Key Question 1. … Several studies mentioned that if wound closure was complete prior to the end of the planned treatment … One study plans to apply dressing with PRP every 3 days until 90% wound healing, with no specific end
  4. hcup-us.ahrq.gov/reports/methods/2019-01.pdf
    January 01, 2019 - The AHRQ QI measures generated for possible inclusion in the QDR are described in Table 1 at the end … the AHRQ PQI software, diabetes must be the principal diagnosis and long-term complications include renal … Exclusions include the following: admissions with a diagnosis code for chronic renal failure and transfers … software, the following cases are excluded: admissions with a principal diagnosis of pressure ulcer stage … with the AHRQ PSI software, the following cases are excluded: obstetric cases; admissions with acute renal
  5. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/autoimmune-disease-rapid-research.pdf
    November 01, 2024 - The program has begun to develop a range of rapid evidence products to assist end users in making specific … At this stage, we excluded articles that did not describe dental treatments, used healthy controls as … Year Title DOI Exclusion Reason Trivedi 2018 Novel PAradigm to improve Inflammatory burden in endstage Renal disease (rePAIR): study protocol for a randomized controlled trial 10.1186/s13063- 018
  6. www.uspreventiveservicestaskforce.org/home/getfilebytoken/oPmYxryXGu2occANaReagc
    August 01, 2022 - Related article at jamanetworkopen.com Author Affiliations: Author affiliations are listed at the end … Diagram: Screening for Latent Tuberculosis Infection in Adults 3275 Excluded at title and abstract stage … 413 Excluded at title and abstract stage 188 Wrong population 48 Wrong intervention 45 Wrong study … (53 included studies) used a mixed- treatment comparison methodology and focused on 2 prespecified end … household or close contacts of persons with active tuberculosis without confirmed LTBI; and persons with renal
  7. www.ahrq.gov/sites/default/files/wysiwyg/teamstepps/diagnosis-improvement/dxsafety-facilitators-guide.pdf
    February 04, 2022 - This reality-based case describes the diagnostic journey of a 49-year-old patient, Joe Kane, with endstage renal disease who is receiving weekly hemodialysis. … Add your Overall Ratings into a Summary Score at the end of the assessment; the range is from 0 to 125 … Summary Score: Add your Overall Rating for each domain into a total score at the end.
  8. www.ahrq.gov/sites/default/files/wysiwyg/teamstepps-program/dx-improvement/dxsafety-facilitators-guide.pdf
    February 04, 2022 - This reality-based case describes the diagnostic journey of a 49-year-old patient, Joe Kane, with endstage renal disease who is receiving weekly hemodialysis. … Add your Overall Ratings into a Summary Score at the end of the assessment; the range is from 0 to 125 … Summary Score: Add your Overall Rating for each domain into a total score at the end.
  9. hcup-us.ahrq.gov/db/nation/nis/NIS_Introduction_2012.jsp
    January 01, 2012 - Standard formulas for a stratified, single–stage cluster sample without replacement should still be used … software packages that perform calculations for numerous statistics arising from the stratified, single–stage … Comorbidity is not present, (1) Comorbidity is present CM_RENLFAIL AHRQ comorbidity measure: Renal … More than 50 percent of AHA respondents report statistics for fiscal years, which often end in June or
  10. effectivehealthcare.ahrq.gov/sites/default/files/infectiousdisease_hi_impact.pdf
    December 01, 2013 - Based on this input, our overall assessment is that this intervention is in the higher end of the high … Based on this input, our overall assessment is that this intervention is in the lower end of the high … users of emtricitabine/tenofovir should be monitored for potential side effects. 48 Decline in renal … Based on this input, our overall assessment is that this intervention is in the higher end of the high … Based on this input, our overall assessment is that this intervention is in the higher end of the high
  11. effectivehealthcare-admin.ahrq.gov/sites/default/files/infectiousdisease_hi_impact.pdf
    December 01, 2013 - Based on this input, our overall assessment is that this intervention is in the higher end of the high … Based on this input, our overall assessment is that this intervention is in the lower end of the high … users of emtricitabine/tenofovir should be monitored for potential side effects. 48 Decline in renal … Based on this input, our overall assessment is that this intervention is in the higher end of the high … Based on this input, our overall assessment is that this intervention is in the higher end of the high
  12. www.uspreventiveservicestaskforce.org/home/getfilebytoken/Xbtq4oDQwVo7KgmSjnnDbz
    November 01, 2021 - primary studies informing the key questions (eMethods in the Supplement) that were pub- lished from the end … sources (eg, reference lists, peer reviewers, other SERs) 7796 Citations excluded at title and abstract stage … Association between early stage colon neoplasms and false-negative results from the fecal immunochemical … Incidental finding of renal masses at unenhanced CT: prevalence and analysis of features for guiding
  13. effectivehealthcare.ahrq.gov/sites/default/files/data-points-7-tables1.pdf
    August 22, 2011 - Ingredient, Age, Gender, and Race Note: An asterisk (*) signifies a small cell count (less than 11); ESRD = endstage renal disease.
  14. effectivehealthcare.ahrq.gov/sites/default/files/data-points-7-tables.pdf
    August 22, 2011 - Ingredient, Age, Gender, and Race Note: An asterisk (*) signifies a small cell count (less than 11); ESRD = endstage renal disease.
  15. effectivehealthcare-admin.ahrq.gov/sites/default/files/data-points-7-tables.pdf
    August 22, 2011 - Ingredient, Age, Gender, and Race Note: An asterisk (*) signifies a small cell count (less than 11); ESRD = endstage renal disease.
  16. effectivehealthcare-admin.ahrq.gov/sites/default/files/data-points-7-tables1.pdf
    August 22, 2011 - Ingredient, Age, Gender, and Race Note: An asterisk (*) signifies a small cell count (less than 11); ESRD = endstage renal disease.
  17. hcup-us.ahrq.gov/db/nation/nis/NISIntroduction2012.pdf
    November 01, 2015 - Standard formulas for a stratified, single-stage cluster sample without replacement should still be … software packages that perform calculations for numerous statistics arising from the stratified, single-stage … (0) Comorbidity is not present, (1) Comorbidity is present CM_RENLFAIL AHRQ comorbidity measure: Renal …  More than 50 percent of AHA respondents report statistics for fiscal years, which often end in
  18. hcup-us.ahrq.gov/db/nation/nis/NIS_Introduction_2013.jsp
    January 01, 2013 - Standard formulas for a stratified, single–stage cluster sample without replacement should still be used … software packages that perform calculations for numerous statistics arising from the stratified, single–stage … Comorbidity is not present, (1) Comorbidity is present CM_RENLFAIL AHRQ comorbidity measure: Renal … More than 50 percent of AHA respondents report statistics for fiscal years, which often end in June or
  19. hcup-us.ahrq.gov/reports/methods/2020-04.pdf
    January 01, 2020 - The AHRQ QI measures generated for possible inclusion in the NHQDR are described in Table 1 at the end … the AHRQ PQI software, diabetes must be the principal diagnosis and long-term complications include renal … software, the following cases are excluded: admissions with a principal diagnosis of pressure ulcer stage … with the AHRQ PSI software, the following cases are excluded: obstetric cases; admissions with acute renal … O43.233 Placenta percreta, third trimester O43.239 Placenta percreta, unspecified trimester O72.0 Third-stage
  20. effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-surv-report-2-noninvasive-nonpharma_0.xlsx
    January 01, 2022 - all six treatment sessions and to attend follow-up visits for at least 12 months (52 weeks) after the end … 11.69), p=NR TSK: 23.02 (6.26) vs. 25.13 (6.85), p=NR NR NR One serious adverse event occurred at the end … within each treatment arm (yoga=A1 and A2, PT=B1 and B2) did not differ in primary outcomes at the end … Recieved 12 weekly sessions of RFCBT at the end of the study. A vs. … sciatica; ongoing pregnancy; hypertension, cardiovascular disease, diabetes mellitus, liver disease, renal